Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06277999
Other study ID # D8820C00001
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date April 22, 2024
Est. completion date October 11, 2024

Study information

Verified date June 2024
Source AstraZeneca
Contact AstraZeneca Clinical Study Information Center
Phone 1-877-240-9479
Email information.center@astrazeneca.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

D8820C00001 is an exploratory, non-interventional, unblinded, observational study evaluating the acceptability, feasibility and performance of methods to collect, transport and test biospecimens in participants ≥ 18 years of age with an active CDI. Participants will also be monitored for recurring episodes of diarrhea and will need to complete validated PROs and study evaluation questionnaires


Description:

The premise of D8820C00001 study is to monitor participants for recurring episodes of diarrhea and evaluate acceptability and feasibility of the use of the digital tools and patient outcome measures. The aim will be to enroll two cohorts of patients; the first will be the Monitoring cohort, enrolling a targeted minimum of 20 and a maximum of 100 participants who will be followed through Day 42, with a screening period from Day -5 to Day 1 (see Section 2.1.1). The second will be the Discard Stool cohort, enrolling up to 200 participants, who will not be followed during the study but who will provide consent for the use of any discarded stool specimens that will not be used for additional laboratory diagnostic testing .


Recruitment information / eligibility

Status Recruiting
Enrollment 100
Est. completion date October 11, 2024
Est. primary completion date October 11, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 130 Years
Eligibility Inclusion Criteria: 1. Male or female participants = 18 years of age at the time of signing the informed consent 2. Participants in the Monitoring and Discard Stool cohorts with an active treated CDI, defined as meeting all of the following: - Either diarrhea, defined as = 3 unformed stools in a 24 hour period, with the stool being measured as Types 5, 6, 7 on the Bristol Stool Scale or evidence of megacolon, or severe ileus. - A positive local stool test results for toxigenic C difficile collected no more than 7 days before entry to the study or evidence of pseudomembranes demonstrated by endoscopy or histopathology. - Receiving SOC therapy (including but not limited to metronidazole, vancomycin, fidaxomicin) for the treatment of CDI, initiated in the prior 5 days, at the time of enrollment. 3. Able to complete all study assessments, and to understand and comply with study requirements/procedures (if applicable, with assistance by caregiver, surrogate, or legally authorized representative, or equivalent representative as locally defined) based on the assessment of the PI 4. Able to complete the Follow-up period through Day 42 based on the assessment of the PI. 5. If able, signed and dated written informed consent prior to any study specific procedures, including screening evaluations for participants who consent to participate in the Monitoring cohort. Ensure that participants who are considered by the Investigator clinically unable to consent at screening and who are entered into the study by the consent of a legally acceptable representative show evidence of assent, as applicable in accordance with local regulations. 6. Signed and dated written information consent prior to collection and testing of stool samples for participants in the Discard Stool cohort Exclusion Criteria: 1. Employees of AstraZeneca, clinical study site, or any other individuals directly involved with the conduct of the study, or immediate family members of such individuals. Employees of the clinical site or immediate families of these individuals not directly involved in the clinical study will be permitted to participate. 2. Deprived of freedom by an administrative or court order, or in emergency setting, or hospitalized involuntarily 3. Absence of suitable venous access for serum sampling

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States Research Site Boston Massachusetts
United States Research Site Boston Massachusetts
United States Research Site Charleston South Carolina
United States Research Site Sacramento California
United States Research Site Saint Louis Missouri

Sponsors (1)

Lead Sponsor Collaborator
AstraZeneca

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants that completed key study activities according to protocol Evaluation of the overall and individual completion rate of procedures and logistics involved in key study activities defined as:
Stool sample collection, transport, and processing.
Serum collection.
Identification of suspected rCDI using the participant monitoring strategy
Cdiff32, CDI-DaySyms and PGI-S PRO questionnaire completion rate during the SOC treatment period.
from Day 1 to Day 42
Secondary Time intervals across stool sample collection logistics All stools counted regardless of multiple stools per participant:
selected percentiles of empirical distribution of time taken for samples to be collected by courier for transport to central lab (split by geography, site, or home)
selected percentiles of empirical distribution of time taken of testing procedure or components thereof
from Day 1 to Day 42
Secondary Participant Experience and site staff evaluation questionnaires Review of Participant Experience and site staff evaluation questionnaires for qualitative and quantitative feedback on factors which affect completion of study activities, including participant acceptability of study activities from Day 1 to Day 42
Secondary Gather information to assess logistics, resourcing and performance of different toxin detection assays (eg. EIA, PCR, CCNA) Number of samples completed in accordance to study protocol, time to complete testing, number of samples tested with stability window from Day 1 to Day 42
See also
  Status Clinical Trial Phase
Recruiting NCT04179201 - Study on Clostridium Difficile Infection in Chinese Patients With Inflammatory Bowel Disease
Completed NCT02563106 - A Study of SYN-004 for the Prevention of C.Diff in Patients With a LRTI Phase 2
Completed NCT00214461 - Safety, Tolerability, and Immunogenicity of a Clostridium Difficile Toxoid Vaccine in Healthy Elderly Volunteers Phase 1
Completed NCT00314951 - Fidaxomicin Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) Phase 3
Completed NCT00328263 - Efficacy and Safety of BIO-K + CL1285 in Prevention of Antibiotic-associated Diarrhea in Hospitalized Adult Patients Phase 3
Completed NCT00127803 - Safety, Tolerability, and Immunogenicity Study of a Clostridium Difficile Toxoid Vaccine in Healthy Adult Volunteers Phase 1
Completed NCT00350298 - Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease Phase 2
Withdrawn NCT05077085 - Bezlotoxumab Versus FMT for Multiple Recurrent CDI Phase 4
Recruiting NCT02681068 - MicroTrans - A Multicenter Registry of Fecal Microbiota Transplantation N/A
Completed NCT00446355 - Clinical Outcomes of Patients With Clostridium Difficile Associated Disease Attributable to Diverse tcdC Genotypes N/A
Terminated NCT00384527 - Study of Nitazoxanide in the Treatment of Clostridium Difficile-associated Disease Phase 3
Completed NCT00269399 - A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) Phase 3
Completed NCT04026009 - Safety and Immunogenicity Study of GSK's Clostridium Difficile Vaccine 2904545A When Administered in Healthy Adults Aged 18-45 Years and 50-70 Years Phase 1
Completed NCT00468728 - PAR-101/OPT-80 Versus Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD) Phase 3